An HCV Vaccine: Can we get there?
|
|
- Sandra Harrington
- 5 years ago
- Views:
Transcription
1 An HCV Vaccine: Can we get there? Andrea L. Cox, MD,PhD Viral Hepatitis Center
2 No Conflicts of Interest
3 Outline Reasons to develop an HCV vaccine What constitutes protective immunity to HCV What challenges exist in HCV vaccine development Overcoming the challenges A prophylactic HCV vaccine is being tested in atrisk subjects for the first time
4 HCV- Do we need a vaccine? Therapies dramatically better but
5 HCV- Do we need a vaccine? Treatment remains expensive and carries some side effects
6 HCV- Do we need a vaccine? Treatment remains expensive and carries side effects Drugs do not provide protection against reinfection
7 HCV- Do we need a vaccine? Treatment remains expensive and carries side effects Drugs do not provide protection against reinfection Finding the people who need treatment remains challenging
8 Identification of HCV Infected people is challenging Infection usually silent until ESLD present
9 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited 5% of those infected world-wide Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
10 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited 5% of those infected world-wide 50% of those infected aware in US (HIV 80%) Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
11 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited 30% of those infected aware in US (HIV 80%) 5% of those infected world-wide Australia, Canada, France, Denmark, and Scotland as models Aggressive screening Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
12 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited 30% of those infected aware in US (HIV 80%) 5% of those infected world-wide Australia, Canada, France, Denmark, and Scotland as models Aggressive screening 60-80% aware Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
13 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited Highest risk groups are marginalized IDUs Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
14 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited Highest risk groups are marginalized IDUs Living in endemic regions of the world Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
15 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited Highest risk groups are marginalized IDUs Living in endemic regions of the world limited access to testing poor needle injection and blood product hygiene Limited access to therapies Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
16 Worldwide HCV Prevalence
17 Identification of HCV Infected people is challenging Infection usually silent until ESLD present Knowledge of infection status limited Highest risk groups are marginalized Treatment in the later stages doesn t reverse all disease Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
18 Eradication of HCV reduces but doesn t eliminate liver failure Van der Meer JAMA 2012; Backus Clin Gastro 2011; Imazeki Hepatology 2003; Shiratori Ann Intern Med 2005; Veldt et al Ann Intern Med 2007; Berenguer Hepatology 2009;
19 HCV- Do we need a vaccine? US Department of HHS says we do US Dept HHS Viral Hepatitis Action Plan 2011: Development of a vaccine that prevents new HCV infections remains a high priority task.
20 HCV- Do we need a vaccine? US Department of HHS says we do US Dept HHS Viral Hepatitis Action Plan 2011: Development of a vaccine that prevents new HCV infections remains a high priority task. Actions to be initiated in 2011: Facilitate development of candidate hepatitis C vaccines designed to induce protective immune responses.
21 What Are Protective Immune Responses? It s in your genes
22 rs C IL-28B allele associated with higher probability of natural clearance of HCV Thomas DL, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798
23 Common host genetic polymorphisms associated with HIV and viral hepatitis outcomes Gene HIV association Hepatitis association CCR5 32 Protective (Dean et al, Science 1996) HBV-protective against persistence (Thio et al, JV 2007) HLA-B*57 HLA-Cw*04 HLA-C promoter SNP Protective (Migueles et al, PNAS 2000) More rapid HIV progression (Carrington et al, Science 1999) Protective (Fellay, Science 2007) HCV-Protective against persistence (Thio et al, JV 2002) HCV-Increased persistence (Thio et al, JV 2002) HCV-possible protection (Thio et. al. unpublished data) IL-18 promoter SNP Protective (Sobti et. al., BJMG, 2011) HCV-protective against persistence in AA (Ping et al, JID 2008)
24 What Are Protective Immune Responses? It s in your genes And the immune response
25 T cell Responses Crucial in Control of HCV HLA association studies Chimpanzee CD8+ and CD4+ T cell depletion Association of breadth and magnitude of T cell response with viral clearance IFN-γ HCV specific CD8 + T cell responses are temporally correlated with reduction in viremia after infection Grakoui et. al, Science 2003, Shoukry et. al. J. Exp Med, 2003, Day et. al. J Virol 2002, Urbani et al Hepatology 2006, Thimme et al, Proc Natl Acad Sci USA 2002
26 The Protective Immune Response Can it be acquired? Reinfection does not always result in clearance- no protective immunity Some evidence that says yes
27 BBAASH Cohort Baltimore Before and After Acute Study of Hepatitis (BBAASH) 18-35yo Active IDU HCV EIA & RNA neg Anti-HCV Ab = black bar HCV = red bar Persistent Infection Spontaneous Clearance
28 Protection from Persistent HCV p = compared to initial infection (P =.001) Osburn et. al. Gastroenterolgy 2010;138:
29 Decreased magnitude of viremia Max Detected HCV RNA (IU/ml) 1e+9 1e+8 1e+7 1e+6 1e+5 1e+4 1e+3 1e+2 1e+1 Primary Infection Osburn et. al. Gastroenterolgy 2010;138: during reinfection P < 0.05 Subsequent Infections includes persistently reinfected subjects
30 Shorter duration of viremia during reinfection Osburn et. al. Gastroenterolgy 2010;138:
31 Broadening of T cell responses in HCV Reinfection P < 0.05 Updated from Osburn et. al. Gastroenterology 2010;138:
32 Repeated HCV Controllers- 83% clear Recurrent detectable viremia with broadening of the immune response: Lower maximum HCV RNA Shorter duration of viremia Subjects who have cleared a fourth, fifth, and sixth infection
33 Super HCV Controllers
34 Is sterilizing immunity required? Sterilizing immunity is a high bar HCV vaccines in animal models have not provided sterilizing immunity When all else fails
35 Lower your standards!
36 Is sterilizing immunity required? Almost all significant disease is from chronic infection After spontaneous clearance, documented reinfection is common and without sequelae Osburn et. al. Gastroenterolgy 2010;138: , Micallef et.al. Journal of Viral Hepatitis 2007; 14:6, , Aitken et. al. Hepatology 2008; 48:6,
37 HCV- Can we make an effective vaccine? Challenges parallel to HIV Highly diverse virus
38 G E D hominoids C A B F a 1c 1 1b HBV 3181 sites 5 F D B G AE A K J HIV 8316 sites C H HCV 9198 sites Ray SC and Thomas DL. PPID 7 th ed, Chapter
39 HCV- Can we make an effective vaccine? Challenges parallel to HIV Highly diverse virus Increasing interest in vaccines that induce robust T cell responses
40 HCV- Can we make an effective vaccine? Challenges parallel to HIV Highly diverse virus Increasing interest in vaccines that induce robust T cell responses Unsafe to use live attenuated or killed virus
41 HCV- Can we make an effective vaccine? Challenges parallel to HIV Highly diverse virus Increasing interest in vaccines that induce robust T cell responses Unsafe to use live attenuated or killed virus Current focus is to use vectors to deliver viral antigens in a system that induces robust innate and adaptive immune responses
42 HCV- Can we make an effective vaccine? Challenges parallel to HIV Highly diverse virus Unsafe to use live attenuated or killed virus Current focus is to use vectors to deliver viral antigens in a system that induces robust innate and adaptive immune responses Preexisting vector immunity limits responses
43 Preventing pre-existing anti-vector immunity from limiting vaccine efficacy Okairos search for novel adenoviral strains in non human primates worldwide Goals: Discover adenoviral vectors that Are highly immunogenic Are easily manufactured to high titers BUT do not stimulate cross reactive immunity (humans rarely exposed)
44 Preventing pre-existing anti-vector immunity from limiting vaccine efficacy Success: Adenoviruses derived from chimpanzees (ChAd) differ from human adenovirus primarily in hexon (surface) proteins, making Ab cross reactivity low many are highly immunogenic
45 Prophylatic vaccines to generate T cell immunity based on viral vectors Low seroprevalence chimpanzee and a human derived Adenoviruses ChAd3, Ad6 MVA attenuated strain, non-replicating in mammalian cells NS3 Protease NS5Bmut AAG Vectored HCV antigen: NSmut Met NS3 NS3 A NS4 B A NS5 B NS3-NS5B (NS = 1985 aa) Several CD4 and CD8 T cell epitopes mapped in humans Most conserved HCV region Genotype I, subtype 1b Aim: induce antiviral immunity with functional characteristics analogous to those associated with viral control in natural infection broadly targeted, durable, functional CD4+CD8+ T cell response
46 HCV Vaccine Healthy Volunteer Trial Summary AdCh3NSmut prime with MVANSmut boost is a highly potent inducer of T cell responses. All individuals responded the vaccination. The majority of subjects developed responses against multiple HCV proteins. Polyfunctional CD4 + and CD8 + T cells are induced. T cells responses across genotypes detected. Vaccines safe and well tolerated. Swadling L et al., Science Translational Medicine; 5 November 2014; 6:(261)
47 Figure 2c
48 Figure 2d
49 VIP: Vaccine is Prevention Design: Double blind, randomized, placebo controlled at JHU and UCSF
50 VIP: Vaccine is Prevention Design: Double blind, randomized, placebo controlled at JHU and UCSF Population: yo male and female active injection drug users at high risk for but not infected with HCV RNA at screening
51 VIP: Vaccine is Prevention Design: Double blind, randomized, placebo controlled at JHU and UCSF Population: yo male and female active injection drug users at high risk for but not infected with HCV RNA at screening Size: Total N=344 (±8)
52 VIP: Vaccine is Prevention Design: Double blind, randomized, placebo controlled at JHU and UCSF Population: yo male and female active injection drug users at high risk for but not infected with HCV RNA at screening Size: Total N=344 (±8) Goal: assessment of safety, induction of HCV specific immune responses, and efficacy in preventing chronic HCV infection
53 VIP: Vaccine is Prevention Design: Double blind, randomized, placebo controlled at JHU and UCSF Population: yo male and female active injection drug users at high risk for but not infected with HCV RNA at screening Size: Total N=344 (±8) Goal: assessment of safety, induction of HCV specific immune responses, and efficacy in preventing chronic HCV infection
54 VIP Design Two injections administered at 0 and 8 weeks: AdCh3NS mut1 & MVA-NS mut Immune responses assessed W0 W8 W = week W88 AdCh3 MVA immune response assessed
55 VIP Design Two injections administered at 0 and 8 weeks: AdCh3NS mut1 & MVA-NS mut Immune responses assessed HCV RNA tested monthly W0 W8 W = week W88 AdCh3 MVA immune response assessed
56 VIP VIP Design Design Subject participation: Non-viremic subjects followed 20 months Viremic subjects referred for Rx, followed 9 months after virus detected or 20 months W0 W8 W = week W88 AdCh3 MVA immune response assessed
57 Conclusions A prophylactic HCV vaccine is needed. Protective immunity likely exists in vivo. As with HIV, it will not be easy to create a successful vaccine. A new prophylactic vaccine is in trials for the first time in at risk subjects- data due out in early 2016
58 Acknowledgements William Osburn Michael Melia Shaneca Bowden Donald Brown Kimberly Page Paula Lum Alice Asher Richard Antrobus Eleanor Barnes Anthony Brown Paul Klenerman Leo Swadling Our Study Subjects Stefania Capone Antonella Folgori Alfredo Nicosia Elisa Scarselli Cinzia Traboni
HCV Vaccine Development
HCV Vaccine Development Andrea L. Cox, MD,PhD Professor of Medicine and Oncology Viral Hepatitis Center Disclosure speaker interests Disclosure of speaker interest No potential conflicts to report HCV-
More informationHCV vaccine: how do we prove it works?
HCV vaccine: how do we prove it works? Kimberly Page, Ph.D. MPH Professor, Chief of Epidemiology, Biostatistics & Preventive Medicine University of New Mexico Health Sciences Center pagek@salud.unm.edu
More informationTherapeutic vaccines for HCV Chasing a Moving Target
Therapeutic vaccines for HCV Chasing a Moving Target Ellie Barnes (Fondation Merieux-Annecy March 213) Do we need a vaccine for HCV? HCV infects 17 million people worldwide Leading cause of end-stage
More informationHCV Vaccine where do we stand? U. Spengler University of Bonn
HCV Vaccine where do we stand? U. Spengler University of Bonn THE IDEAL GOAL: The vaccine should induce sterilizing immunity A MORE REALISTIC GOAL: Prevention of chronic persistent infection Feinstone
More informationHow to be the Perfect Host. and How they deal with us
How to be the Perfect Host How we deal with viruses and How they deal with us 3 Parts Intro to viruses and immunity HCV making a vaccine HIV providing a cure What is a virus? A piece of bad news wrapped
More informationDeliberate release of the GMO AdCh3NSmut1 in a proposed clinical trial
Environmental Risk Assessment Deliberate release of the GMO AdCh3NSmut1 in a proposed clinical trial Conducted according to the principles described in: S.I. No. 500 of 2003 Genetically Modified Organisms
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationTHE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV
THE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV Philippa Matthews Consultant in Infectious Diseases & Microbiology SUPPRESSION CO-EVOLUTION ESCAPE Host factors associated with the clinical course
More information9/29/2014. Patterns of hepatitis C virus RNA levels during acute infection: the InC 3 study. Background. Background. Background
atterns of hepatitis C virus RNA levels during acute infection: the InC 3 study Behzad Hajarizadeh 1, Bart Grady 2, Kimberly age 3, Arthur Y. Kim 4, Barbara H. McGovern 5,6, Andrea L. Cox 7, Thomas M.
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationAdvances in Hepatitis C Virus Therapeutics HBV HIV HCV. Advances in HCV Therapeutics. Greg Dore. Viral Hepatitis Clinical Research Program
Advances in Hepatitis C Virus Therapeutics Greg Dore Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and Clinical Research Hepatitis C notifications: 199-23 Estimates of BBV
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationThe myths and realities of hepatitis C for people who inject drugs
The myths and realities of hepatitis C for people who inject drugs Margaret Hellard, Centre for Population Health Burnet Institute Outline of today s presentation Background information Discuss some of
More informationDevelopment of live attenuated pediatric RSV vaccines
Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationSupporting Information
Supporting Information Honegger et al. /pnas.0 HCV proteins Core E E P NS NS NSA NSB NSA NSB HCV peptide pools 9 Fig. S. HCV proteins represented in the nine peptide pool arrays used for the IFN-γ ELISpot
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationA Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination
A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination Sponsor: University of Oxford EudraCT No.: 2014-000730-30 REC: South Central Oxford A REC
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationProspects for Prophylactic and Therapeutic Vaccines Against Hepatitis C Virus
SUPPLEMENT ARTICLE Prospects for Prophylactic and Therapeutic Vaccines Against Hepatitis C Virus Stephen M. Feinstone, 1 Dale J. Hu, 2,a and Marian E. Major 1 1 Division of Viral Products, Center for Biologics
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationReview on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationAcute hepatitis C The European Experience
Acute hepatitis C The European Experience Dr Emma Page MBBS MRCP MD(Res) Chelsea and Westminster Hospital, London AHC the European Experience 1. Epidemic 2. CNS sequelae 3. Incidence 4. Re-infection Reports
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationEPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE
EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious
More informationHIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
More informationInterrogating the Human CD8+ T cell Response in HCV Infection
Interrogating the Human CD8+ T cell Response in HCV Infection by Kelly P. Burke A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationThe Chimpanzee Model Of HCV: Antiviral Therapy
The Chimpanzee Model Of HCV: Antiviral Therapy Antiviral Therapies in Chimpanzees PEG IFN + Ribavirin STAT C with DAA Protease Inhibitors Nucleoside analogues Polymerase Inhibitors NS5A Inhibitors Immunomodulators
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationCo-evolution of host and pathogen: HIV as a model. Can Keşmir Theoretical Biology/Bioinformatics Utrecht University, NL
Co-evolution of host and pathogen: HIV as a model Can Keşmir Theoretical Biology/Bioinformatics Utrecht University, NL c.kesmir@bio.uu.nl Outline Does HIV adapt to monomorphic human molecules? Polymorphic
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationSupplementary Online Content
Supplementary Online Content Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
More informationThe early pathogenesis of FMD and the implications for control measures
The early pathogenesis of FMD and the implications for control measures Luis L. Rodriguez and Jonathan Arzt Foreign Animal Disease Research Unit, USDA-ARS Plum Island Animal Disease Center, New York, USA.
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationComparison of HCV Recurrent Viremia Rates in All-Oral and Interferon-Based Regimens
Comparison of HCV Recurrent Viremia Rates in All-Oral and Interferon-Based Regimens Presented by: Tyler Raycraft Doctor of Medicine Candidate, 2019 University of British Columbia Clinical Researcher Vancouver
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationDiagnosis of Acute HCV Infection
Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationHepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital
Hepatitis B virus infection Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Chronic Hepatitis B - are we in the same situation as hepatitis C? Treatment of chronic hepatitis
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationIs Elimination of Hepatitis C Possible?
Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?
More informationThe silent syndemic of opioids and HCV
The silent syndemic of opioids and HCV Arthur Y. Kim, MD Division of Infectious Diseases, Massachusetts General Hospital Associate Professor of Medicine, Harvard Medical School Northeast Epidemiology Conference
More informationClinical utility of NGS for the detection of HIV and HCV resistance
18 th Annual Resistance and Antiviral Therapy Meeting v Professor Janke Schinkel Academic Medical Centre, Amsterdam, The Netherlands Thursday 18 September 2014, Royal College of Physicians, London Clinical
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationVIRUSES AND CANCER Michael Lea
VIRUSES AND CANCER 2010 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review
More informationEbola Vaccines and Vaccination
Ebola Vaccines and Vaccination Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination September 30, 2015 SECTION C: CONCLUSIONS AND RECOMMENDATIONS
More informationTHE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O.
THE CHANGING LANDSCAPE OF HEPATITIS INFECTION Michael E. Herman D.O. What s New? For Primary Care Providers Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationHepatitis B (and D) Cure Strategies: How far are we?
Hepatitis B (and D) Cure Strategies: How far are we? Heiner Wedemeyer Dept. of Gastroenterology and Hepatology Essen University Hospital International Hepatitis E Symposium February 14-16, 2019 H. Wedemeyer
More informationJournal of Infectious Diseases Advance Access published April 15, 2015
Journal of Infectious Diseases Advance Access published April 15, 2015 1 Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC 3 study Rachel Sacks-Davis 1,2, Jason Grebely 3,
More informationHepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review
Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission
More informationOriginally published as:
Originally published as: Ratsch, B.A., Bock, C.-T. Viral evolution in chronic hepatitis B: A branched way to HBeAg seroconversion and disease progression? (2013) Gut, 62 (9), pp. 1242-1243. DOI: 10.1136/gutjnl-2012-303681
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationAnti-HBc: state of the art what is the CORE of the issues?
Anti-HBc: state of the art what is the CORE of the issues? Robert G Gish MD Adjunct Professor Stanford University Medical Director Hepatitis B Foundation Disclosures: See robertgish.com If you wish an
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationGenetic Determinants in HCV
Genetic Determinants in HCV Lynn E. Taylor, MD Assistant Professor of Medicine Warren Alpert Medical School of Brown University The Miriam Hospital Providence, RI April 27, 2011 Disclosure My presentation
More informationHCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud
HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationFoot and Mouth Disease Control, A vaccine perspective. John Barlow, DVM PhD
Foot and Mouth Disease Control, A vaccine perspective John Barlow, DVM PhD john.barlow@uvm.edu May 28, 2015 Countries in which FMD was reported to the OIE between 1990 and 2002 Antigenic variation is common
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationMANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman
MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More information